Evidence for Natriuretic Peptides a and B as Non-Invasive Markers in Congenital and Valvular Heart Disease

Kotaška, Karel; Průša, Richard

doi:10.5507/bp.2010.006

Cited by 1 publication

(1 citation statement)

References 19 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ANP is produced mainly in atria, BNP/ NT-proBNP predominantly in ventricles. In cardiology, natriuretic peptides are routinely used in diagnostics and management of cardiac dysfunction and heart failure [45][46][47] . Normal plasma BNP/NT-proBNP concentrations practically exclude heart failure due to high negative predictive value of the test 48,49 .…”

Section: Natriuretic Peptides As Markers Of Ct-induced Cardiotoxicitymentioning

confidence: 99%

Biomarkers for the early detection of anthracycline-induced cardiotoxicity: current status

Horáček¹,

Vašatová²,

Pudil³

et al. 2014

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

Background. Cardiotoxicity is a well-known and potentially serious complication of anticancer therapy. Anthracyclinebased chemotherapy represents the greatest risk. Early detection of cardiotoxicity is crucial for applying preventive and supportive therapeutic strategies. Methods and Results. Various methods have been recommended for monitoring of cardiotoxicity. In our conditions, echocardiography and electrocardiography are routinely used. However, this approach shows low sensitivity for the early prediction of cardiomyopathy when the possibilities of appropriate management could still improve the patient's outcome. Recently, biomarkers of cardiac injury have been investigated in the assessment of chemotherapy-induced cardiotoxicity. Cardiospecific biomarkers, such as cardiac troponins, show high diagnostic efficacy in the early subclinical phase of the disease before the clinical onset of cardiomyopathy. Increase in their concentrations correlates with disease severity. As for natriuretic peptides, some studies, including ours, have shown promising results. Definitive evidence of their diagnostic and prognostic role in this context is still lacking and natriuretic peptides have not been routinely used for monitoring of cardiotoxicity in clinical practice. Other perspective biomarkers of cardiotoxicity in oncology are under study, especially heart-type fatty acid-binding protein (H-FABP) and glycogen phosphorylase BB (GPBB). Our studies using GPBB have provided encouraging results. However, the available data are limited and their practical use in this context cannot be recommended until their clinical efficacy is clearly defined. Conclusions. This review covers the current status of biomarkers for the early detection of anthracycline-induced cardiotoxicity. The authors present in brief, their own experience with multiple biomarkers in the detection of cardiotoxicity.

show abstract

Section: Natriuretic Peptides As Markers Of Ct-induced Cardiotoxicitymentioning

confidence: 99%

Biomarkers for the early detection of anthracycline-induced cardiotoxicity: current status

Horáček¹,

Vašatová²,

Pudil³

et al. 2014

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

show abstract

Evidence for Natriuretic Peptides a and B as Non-Invasive Markers in Congenital and Valvular Heart Disease

Cited by 1 publication

References 19 publications

Biomarkers for the early detection of anthracycline-induced cardiotoxicity: current status

Biomarkers for the early detection of anthracycline-induced cardiotoxicity: current status

Contact Info

Product

Resources

About